69O Stock Overview
A clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Aelis Farma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.23 |
| 52 Week High | €13.10 |
| 52 Week Low | €1.00 |
| Beta | 0.62 |
| 1 Month Change | 7.42% |
| 3 Month Change | -46.98% |
| 1 Year Change | -90.47% |
| 3 Year Change | -89.85% |
| 5 Year Change | n/a |
| Change since IPO | -90.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 69O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 23.0% | -0.3% | 0.8% |
| 1Y | -90.5% | -12.7% | 14.6% |
Return vs Industry: 69O underperformed the German Biotechs industry which returned -12.3% over the past year.
Return vs Market: 69O underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| 69O volatility | |
|---|---|
| 69O Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 69O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 69O's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 28 | Pier Piazza | www.aelisfarma.com |
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Aelis Farma SA Fundamentals Summary
| 69O fundamental statistics | |
|---|---|
| Market cap | €16.86m |
| Earnings (TTM) | -€7.46m |
| Revenue (TTM) | €5.56m |
3.0x
P/S Ratio-2.3x
P/E RatioIs 69O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 69O income statement (TTM) | |
|---|---|
| Revenue | €5.56m |
| Cost of Revenue | €0 |
| Gross Profit | €5.56m |
| Other Expenses | €13.02m |
| Earnings | -€7.46m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 22, 2025
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 100.00% |
| Net Profit Margin | -134.05% |
| Debt/Equity Ratio | 49.4% |
How did 69O perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 20:33 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aelis Farma SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| David Seynnaeve | Degroof Petercam |
| Martial Descoutures | ODDO BHF Corporate & Markets |